Canon BioMedical, Melville, NY, has announced an exclusive distribution agreement with Molecular Biology Systems BV, Scottweg, the Netherlands, to market the latter’s NextGenPCR instrument, consumables, and accessories in the United States and Canada.

Molecular Biology Systems describes its next-generation polymerase chain reaction (PCR) technology as “the first real advance in thermal cycling in 15 years.”

Snyder

Dennis Snyder, Canon Biomedical.

According to the company, the NextGenPCR technology reduces the time-consuming process of DNA amplification from hours to just minutes. Using the NextGenPCR system, a three-step, 30-cycle protocol to amplify a 100-base pair fragment, for example, can be completed in less than 2 minutes.

“Canon BioMedical is committed to empowering the biomedical research community by marketing innovative technologies,” says Dennis Snyder, senior director of global commercial operations at Canon BioMedical.

“MBS shares in our commitment to high-quality products that improve the laboratory experience,” Snyder adds. “Researchers want answers as fast as possible, and offering the NextGenPCR products to our customers will shorten their protocols without requiring them to change their procedures.”

de Vos

Gert de Vos, Molecular Biology Systems.

“Entering the US and Canadian markets is a key part of our strategy,” says Gert de Vos, founder and CEO of Molecular Biology Systems. “We have been impressed with Canon BioMedical’s rapid growth and continuing ambition, and are therefore delighted to have them as our launch partner.”

For more information, visit Canon BioMedical.